Semarvl vs Wegovy: Comparison Guide

Semarvl vs Wegovy: A Clear Comparison for India

The world of health and wellness is buzzing with talk of a medication called semaglutide. In India, this conversation often involves two names: Semarvl and Wegovy. If you're trying to understand the difference, you're not alone. Both are related to semaglutide, but they are not the same.

This guide offers a practical, evidence-aware comparison to help you understand the key differences and similarities. It’s designed to prepare you for a more informed conversation with your doctor about your health goals. Consult your healthcare provider before starting any medication.

What is Semaglutide? The Common Ground

At the heart of both Semarvl and Wegovy is the same active ingredient: semaglutide. It belongs to a class of medications known as GLP-1 (glucagon-like peptide-1) receptor agonists.

In simple terms, semaglutide works by mimicking a hormone your gut naturally releases after you eat. This has a few key effects:

• It helps the pancreas release the right amount of insulin to manage blood sugar levels.
• It slows down the process of food leaving your stomach, which helps you feel full for a longer period.
• It acts on areas of the brain that regulate appetite, reducing food cravings and hunger.

Because of this mechanism, semaglutide has proven effective for both managing type 2 diabetes and supporting chronic weight management. The difference between brands like Semarvl and Wegovy lies in their specific formulation, approved use, and dosage.

Semarvl vs. Wegovy: The Key Differences

While they share an active ingredient, Semarvl and Wegovy may be distinct products with different approved uses and doses. Understanding these differences is crucial.

Approved Uses and Indications

This is perhaps the most important distinction.

Semarvl is a name used for a semaglutide product in India. As of October 2026 we could not find a company announcement or regulatory listing for a brand called Semarvl, so we cannot confirm who makes it or what it is approved for. A March 2026 Medical Dialogues list of expected Indian semaglutide brands includes a similarly spelled name, Semaryl, from Intas Pharmaceuticals, so check the spelling on your prescription. (Dr. Reddy's Laboratories, for example, sells its semaglutide as Obeda, approved in India for type 2 diabetes.) Before using any product sold under this name, ask your doctor or pharmacist to confirm the manufacturer, the approved use and the strength from the pack. Many Indian semaglutide brands launched since March 2026 are approved for type 2 diabetes, and some also for weight management.

Wegovy, from the global pharmaceutical company Novo Nordisk, was specifically developed and studied for chronic weight management. In countries where it is approved, it is indicated for adults and adolescents with obesity or who are overweight with at least one weight-related health condition (like high blood pressure or type 2 diabetes).

Using a medication for a purpose other than its approved indication is known as "off-label" use. This is a medical decision that can only be made by a qualified doctor after carefully weighing the potential benefits and risks for an individual patient.

Dosage and Strength

The dose of semaglutide is a critical factor in its effect, and this is where Semarvl and Wegovy differ significantly.

Wegovy is a high-dose formulation. The treatment plan involves a gradual increase in the weekly dose over several months, starting at 0.25 mg and moving up to a final maintenance dose of 2.4 mg once a week. This specific high dose was studied in large-scale clinical trials (the STEP trials) for its effectiveness in weight management.

Semarvl: we could not verify its strengths. Semaglutide brands approved in India for type 2 diabetes generally use the diabetes doses (in India, Ozempic is sold at 0.25 mg, 0.5 mg and 1 mg). These doses can also lead to some weight loss, but the 2.4 mg dose studied for weight management in the STEP trials is used by weight-management products such as Wegovy and some Indian brands approved for weight management.

Availability in India

Your ability to access a medication is a fundamental part of the picture.

Semarvl: we could not confirm that a product with this name has been launched in India. Only buy semaglutide from a licensed pharmacy with a prescription.

Wegovy was launched in India by Novo Nordisk on June 24, 2025, in five once-weekly strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg). In India it is approved for long-term weight management and, in adults with established heart disease and obesity or overweight, to lower the risk of major cardiovascular events. It is available by prescription.

Understanding Efficacy and Side Effects

Because the active ingredient is the same, the general profile for effectiveness and side effects is similar, but the dosage plays a major role.

How Effective Are They?

The effectiveness of semaglutide for weight loss is strongly linked to the dose. In the STEP 1 trial in adults with obesity or overweight without diabetes, the 2.4 mg weekly dose led to an average weight loss of 14.9% of body weight over 68 weeks (versus 2.4% with placebo), alongside lifestyle changes.

Lower doses of semaglutide, like those used for type 2 diabetes, have also been shown to help with weight loss in people with type 2 diabetes. However, the amount of weight loss is generally less than what is observed with the higher 2.4 mg dose specifically formulated for weight management. A doctor can interpret the clinical data based on your specific health needs.

Potential Side Effects

Like any medication, semaglutide has potential side effects. The most common ones are gastrointestinal and include:

• Nausea
• Diarrhoea
• Vomiting
• Constipation
• Abdominal pain

These side effects are often mild to moderate and tend to be most noticeable when starting the medication or increasing the dose. They often decrease over time as your body adjusts. It is essential to be under a doctor's care to monitor and manage any side effects you may experience.

Seek urgent medical help for severe stomach pain that does not go away (it may spread to your back), signs of a serious allergic reaction, or vomiting so much that you cannot keep fluids down. Low blood sugar is more likely if you also take insulin or a sulfonylurea, and people with diabetic eye disease should report any vision changes. Semaglutide is not used in pregnancy, and you should not use it if you or a family member has had medullary thyroid cancer or you have MEN 2. Tell your doctor or anaesthetist that you take it before any surgery or sedation.

Making an Informed Decision

Choosing a path for your health is a significant decision that should never be made alone. These medications are powerful tools, not simple solutions, and they work best as part of a comprehensive plan.

Your doctor is the only person qualified to determine if a medication like semaglutide is right for you. They will consider your overall health, medical history, primary goal (diabetes or weight management), and what treatments are appropriate and available.

Remember, lifestyle remains the foundation of good health. A balanced diet, regular physical activity, and healthy habits are essential for long-term success, whether you are taking medication or not.

Consult your healthcare provider before starting any medication.

The Takeaway

To summarize the key points:

• Common Ground: Both Semarvl and Wegovy contain the same active drug, semaglutide.
• Different Purpose: Wegovy is designed and dosed specifically for chronic weight management. We could not verify Semarvl's approved use, so confirm it with your doctor or pharmacist.
• Different Dose: Wegovy uses a maintenance dose of up to 2.4 mg for weight management, which is higher than the doses used for type 2 diabetes.
• Availability: Wegovy has been available in India by prescription since June 2025. We could not confirm a launch of a product called Semarvl.

Navigating your health journey requires clear information and expert guidance. This comparison is a starting point. The most important next step is a conversation with a trusted healthcare professional who can help you create a safe and effective plan tailored to you.

Sources

• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
• https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• https://biospectrumindia.com/news/95/26285/novo-nordisk-announces-launch-of-injectable-semaglutide-for-weight-management-in-india.html
• https://biospectrumindia.com/news/73/27524/dr-reddys-laboratories-announces-launch-of-dcgi-approved-semaglutide-injection-obeda-for-type-2-diabetes.html
• https://www.thenationalnews.com/health/2025/12/12/ozempic-india-weight-loss-drug/